US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Merus N.V.

< Previous 1 2 Next >
News headline image
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus to Present at the 2025 Wells Fargo Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus N.V. Announces Pricing of Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus N.V. Announces Proposed Public Offering of Common Shares
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus to Present at BofA Securities 2025 Health Care Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire
Tickers BHVN MRUS
News headline image
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Receives FDA extension of PDUFA for zenocutuzumab
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
News headline image
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Tickers MRUS
< Previous 1 2 Next >